UNSPSC 51171984: Agalsidase beta

A drug indicated for use in patients with Fabry disease.

UNSPSC 51171984 Agalsidase beta is a Commodity code that captures pharmaceutical products procured by state and local agencies, though recent state and local solicitations under this code reveal fragmented and limited direct demand. The three recent opportunities in the block show a mismatch between the code's nominal scope—a single enzyme replacement therapeutic—and the actual purchasing activity: Collin County (Texas) is procuring offender specimen collection and drug testing services under an RFP due July 23, 2026; the Texas Health and Human Services Commission issued a Request for Information on March 27, 2026 (response due April 3, 2026) exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and over-the-counter products through authorized wholesalers. The first two opportunities are not pharmaceutical supply contracts in the traditional sense, and none of them explicitly reference agalsidase beta or enzyme replacement therapies.

The geographic spread of recent activity spans Texas and Minnesota, with the MMCAP cooperative including participating state and local government facilities in Oregon as well. The Collin County RFP for drug testing services (estimated contract value $600,000, two-year term commencing September 1, 2026 with three optional one-year renewals) represents direct county-level procurement, while the Texas HHS RFI and MMCAP RFP reflect state-level and multistate cooperative strategies. The MMCAP contract, with evaluations weighted heavily toward price competitiveness (75 percent), requires vendors to maintain relationships with three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act certifications. The code shows no recent activity from school districts, transit authorities, or other typical state and local issuing bodies, and no solicitation material directly references agalsidase beta or similar specialty pharmaceuticals. The mismatch between the code's nominal scope and the actual work being solicited suggests this code captures only tangential or indirect state and local pharmaceutical procurement activity, if any.